+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach



Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach



Pharmacogenomics 11(8): 1169-1179



Patients with metastatic colorectal carcinoma (mCRC) carrying activating mutations of the KRAS gene do not benefit from treatment with anti-EGF receptor monoclonal antibodies. Therefore, KRAS mutation testing of mCRC patients is mandatory in the clinical setting to aid in the choice of appropriate therapy. We developed a cost-effective approach for the determination of KRAS mutations in codons 12 and 13 in clinical practice based on a sensitive PCR/sequencing technique and the commercially available real-time PCR-based Therascreen kit (DxS Ltd). The PCR/sequencing test was able to detect 10% mutant DNA in a background of wild-type DNA. By using this assay, we determined the mutational status of KRAS in 527 out of 540 (97.6%) formalin-fixed paraffin-embedded tissues from mCRC patients. PCR/sequencing was not conclusive in 13 cases, in which low-intensity peaks suggestive of potential mutations were identified. The DxS assay, which showed a sensitivity of 1%, identified mutations in 11 out of 13 inconclusive cases. Interestingly, five of these 11 cases showed high levels of DNA fragmentation. No significant difference was found in the ability of PCR/sequencing and DxS to identify KRAS mutations within 160 cases with more than 30% tumor cells. However, in 24 samples with less than 30% tumor cells, DxS showed an higher sensitivity. In conclusion, our findings suggest that PCR/sequencing can be used for mutational analysis of the majority of tumor samples that have more than 30% tumor cell content, whereas more sensitive and expensive tests should be reserved for inconclusive cases and for samples with a low amount of tumor cells.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052517187

Download citation: RISBibTeXText

PMID: 20712532

DOI: 10.2217/pgs.10.86


Related references

A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations: A Morphology-Based Approach in Colorectal Carcinoma. Yearbook of Pathology and Laboratory Medicine 2011: 319-320, 2011

A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. Journal of Molecular Diagnostics 12(3): 292-299, 2010

Comparison of real-time PCR-optimized oligonucleotide probe method and Sanger sequencing for detection of KRAS mutations in colorectal and lung carcinomas. Zhonghua Bing Li Xue Za Zhi 41(9): 599-602, 2013

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. Journal of Cellular and Molecular Medicine 14(8): 2122-2131, 2011

Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. Genes, Chromosomes & Cancer 52(5): 503-511, 2013

Detection of KRAS gene mutations in colorectal carcinoma: a study of 6 364 patients. Zhonghua Bing Li Xue Za Zhi 43(9): 583-587, 2015

Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. Journal of Molecular Diagnostics 13(1): 64-73, 2011

The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. Biochemical and Biophysical Research Communications 395(1): 158-162, 2010

Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas. Zhonghua Bing Li Xue Za Zhi 43(2): 77-82, 2014

Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. Journal of Pathology 219(4): 435-445, 2010

Real-Life Distribution of KRAS and NRAS Mutations in Metastatic Colorectal Carcinoma from French Routine Genotyping. Cancer Epidemiology, Biomarkers & Prevention 24(9): 1416-1418, 2016

A PNA-mediated clamping PCR for routine detection of KRAS mutations in colorectal carcinoma. International Journal of Biological Markers 29(1): E55-E61, 2014

Detection of KRAS,NRAS and BRAF gene mutations in colorectal carcinoma. Zhonghua Bing Li Xue Za Zhi 44(4): 254-257, 2015

Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma. Zhonghua Bing Li Xue Za Zhi 41(9): 590-594, 2013

Comparative screening of K-ras mutations in colorectal cancer and lung cancer patients using a novel real-time PCR with ADx-K-ras kit and Sanger DNA sequencing. Cell Biochemistry and Biophysics 62(3): 415-420, 2012